nach oben

Erschienen in:

02.09.2022 | Original Article

Comorbidities in Friedreich ataxia: incidence and manifestations from early to advanced disease stages

verfasst von: Mario Fichera, Anna Castaldo, Alessia Mongelli, Gloria Marchini, Cinzia Gellera, Lorenzo Nanetti, Caterina Mariotti

Erschienen in: Neurological Sciences | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Friedreich’s ataxia (FA) is the most common hereditary ataxia, characterized by multisystemic manifestations including neurological, cardiological, and skeletal abnormalities. In this study, we aimed to analyze the incidences of disease-related and unrelated comorbidities occurring in different stages of the disease progression.

Methods

We analyzed longitudinal data from a 10-year prospective observational study in a cohort of 175 FA patients with disease onset < 25 years. We analyzed the time of diagnosis for the most frequently reported medical conditions, with respect to age and disease duration of each patient.

Results

In the early stage of the disease, scoliosis (53.3%), hypertrophic cardiomyopathy (46.7%), and pes cavus (33.3%) were the most frequently diagnosed conditions, sometimes occurring even before the onset of ataxia. Diabetes, bone fractures, and depression have the same incidence at all disease stages. In patients with > 20 years of disease duration, the most frequent complications were hearing and visual loss (20% and 26%), arrhythmias (16%), and psychosis (18%). Thirteen patients presented hallucinations/delusions in the absence of neurological acute events or mental illness predisposing to psychotic manifestations. Six of these patients fulfill the diagnostic criteria for Charles Bonnet syndrome.

Conclusions

Incidence of FA-related medical conditions varies according to disease duration. In patients with very long disease duration, we observed an unexpectedly high incidence of visual and auditory pseudo-hallucinations that were not previously reported in FA patients. We hypothesized that these late complications may be possibly related to the severe sensory deafferentation syndrome observed in the advanced stages of FA disease.

Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254):1423–1427. https://doi.org/10.1126/science.271.5254.1423CrossRefPubMed

Gellera C, Castellotti B, Mariotti C, Mineri R, Seveso V, Didonato S, Taroni F (2007) Frataxin gene point mutations in Italian Friedreich ataxia patients. Neurogenetics 8(4):289–299. https://doi.org/10.1007/s10048-007-0101-5CrossRefPubMed

Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, Saffery R, Galati JC, Wong NC, Craig JM, Lynch DR et al (2012) FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol 71(4):487–497. https://doi.org/10.1002/ana.22671CrossRefPubMed

Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P (2013) Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem 126:103–117. https://doi.org/10.1111/jnc.12317CrossRefPubMed

Cook A, Giunti P (2017) Friedreich’s ataxia: clinical features, pathogenesis and management. Br Med Bull 124(1):19–30. https://doi.org/10.1093/bmb/ldx034CrossRefPubMedPubMedCentral

Pousset F, Legrand L, Monin ML, Ewenczyk C, Charles P, Komajda M, Brice A, Pandolfo M, Isnard R, du Montcel ST et al (2015) A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol 72(11):1334–1341. https://doi.org/10.1001/jamaneurol.2015.1855CrossRefPubMed

Delatycki MB, Holian A, Corben L, Rawicki HB, Blackburn C, Hoare B, Toy M, Churchyard A (2005) Surgery for equinovarus deformity in Friedreich’s ataxia improves mobility and independence. Clin Orthop Relat Res 138–141.https://doi.org/10.1097/01.blo.0000150339.74041.0e

Simon AL, Meyblum J, Roche B, Vidal C, Mazda K, Husson I, lharreborde B, (2019) Scoliosis in patients with Friedreich ataxia: results of a consecutive prospective series. Spine Deform 7(5):812–821. https://doi.org/10.1016/j.jspd.2019.02.005CrossRefPubMed

Dürr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M (1996) Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 335(16):1169–1175. https://doi.org/10.1056/NEJM199610173351601CrossRefPubMed

10.

Rummey C, Farmer JM, Lynch DR (2020) Predictors of loss of ambulation in Friedreich’s ataxia. EClinicalMedicine 18:100213. https://doi.org/10.1016/j.eclinm.2019.11.006CrossRefPubMedPubMedCentral

11.

Reetz K, Dogan I, Hohenfeld C, Didszun C, Giunti P, Mariotti C, Durr A, Boesch S, Klopstock T, de Rivera R, Garrido FJ et al (2018) Nonataxia symptoms in friedreich ataxia: report from the Registry of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS). Neurology 91(10):917–930. https://doi.org/10.1212/WNL.0000000000006121CrossRef

12.

Regner SR, Lagedrost SJ, Plappert T, Paulsen EK, Friedman LS, Snyder ML, Perlman SL, Mathews KD, Wilmot GR, Schadt KA et al (2012) Analysis of echocardiograms in a large heterogeneous cohort of patients with Friedreich ataxia. Am J Cardiol 109(3):401–405. https://doi.org/10.1016/j.amjcard.2011.09.025CrossRefPubMed

13.

Corben LA, Ho M, Copland J, Tai G, Delatycki MB (2013) Increased prevalence of sleep-disordered breathing in Friedreich ataxia. Neurology 81(1):46–51. https://doi.org/10.1212/WNL.0b013e318297ef18CrossRefPubMed

14.

Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M et al (2015) Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol 14(2):174–182. https://doi.org/10.1016/S1474-4422(14)70321-7CrossRefPubMed

15.

Indelicato E, Nachbauer W, Eigentler A, Amprosi M, Matteucci Gothe R, Giunti P, Mariotti C, Arpa J, Durr A, Klopstock T et al (2020) Onset features and time to diagnosis in Friedreich’s ataxia. Orphanet J Rare Dis 15(1):198. https://doi.org/10.1186/s13023-020-01475-9CrossRefPubMedPubMedCentral

16.

Reetz K, Dogan I, Hilgers RD, Giunti P, Mariotti C, Durr A, Boesch S, Klopstock T, de Rivera FJR, Schöls L et al (2016) Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol 15(13):1346–1354. https://doi.org/10.1016/S1474-4422(16)30287-3CrossRefPubMed

17.

Reetz K, Dogan I, Hilgers RD, Giunti P, Parkinson MH, Mariotti C, Nanetti L, Durr A, Ewenczyk C, Boesch S et al (2021) Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol 20(5):362–372. https://doi.org/10.1016/S1474-4422(21)00027-2CrossRefPubMed

18.

Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66(8):1717–1720. https://doi.org/10.1212/01.wnl.0000219042.60538.92CrossRefPubMed

19.

Hedges TR (2007) Charles Bonnet, his life, and his syndrome. Surv Ophthalmol 52(1):111–114. https://doi.org/10.1016/j.survophthal.2006.10.007CrossRefPubMed

20.

Fortuna F, Barboni P, Liguori R, Valentino ML, Savini G, Gellera C, MariottiC RG, Tonon C, Manners D et al (2009) Visual system involvement in patients with Friedreich’s ataxia. Brain 132(1):116–123. https://doi.org/10.1093/brain/awn269CrossRefPubMed

21.

Istituto Superiore di Sanità, EpiCentro (2022). https://www.epicentro.iss.it/en. Accessed 30 June 2022.

22.

White M, Lalonde R, Botez-Marquard T (2000) Neuropsychologic and neuropsychiatric characteristics of patients with Friedreich’s ataxia. Acta Neurol Scand 102(4):222–226. https://doi.org/10.1034/j.1600-0404.2000.102004222.xCrossRefPubMed

23.

Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I et al (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:21–27. https://doi.org/10.1111/j.1600-0047.2004.00327.xCrossRef

24.

Hamedani AG, Pelak VS (2019) The Charles Bonnet syndrome: a systematic review of diagnostic criteria. Curr Treat Options Neurol 21(9):41. https://doi.org/10.1007/s11940-019-0582-1CrossRefPubMed

25.

Alvarez Perez P, Garcia-Antelo MJ, Rubio-Nazabal E (2017) “Doctor, I hear music”: a brief review about musical hallucinations. Open Neurol J 11:11–14. https://doi.org/10.2174/1874205X01711010011CrossRefPubMedPubMedCentral

26.

Kolarova H, Catarino CB, Priglinger C, Klopstock T (2019) Charles Bonnet syndrome in Leber’s hereditary optic neuropathy. J Neurol 266(3):777–779. https://doi.org/10.1007/s00415-019-09205-3CrossRefPubMed

27.

Peters D, Molander S, Lomo T, Singh A (2021) Charles Bonnet syndrome in patients with open-angle glaucoma: prevalence and correlation to visual field loss. Ophthalmol Glaucoma 5(3):337–344. https://doi.org/10.1016/j.ogla.2021.10.010CrossRefPubMed

28.

van der Werf M, van Boxtel M, Verhey F, Jolles J, Thewissen V, van Os J (2007) Mild hearing impairment and psychotic experiences in a normal aging population. Schizophr Res 94(1–3):180–186. https://doi.org/10.1016/j.schres.2007.04.006CrossRefPubMed

29.

Jones L, Moosajee M (2021) Visual hallucinations and sight loss in children and young adults: a retrospective case series of Charles Bonnet syndrome. Br J Ophthalmol 105(11):1604–1609. https://doi.org/10.1136/bjophthalmol-2020-317237CrossRefPubMed

30.

Marschall TM, Brederoo SG, Ćurčić-Blake B, Sommer IEC (2020) Deafferentation as a cause of hallucinations. Curr Opin Psychiatry 33(3):206–211. https://doi.org/10.1097/YCO.0000000000000586CrossRefPubMed

31.

Hahamy A, Wilf M, Rosin B, Behrmann M, Malach R (2021) How do the blind “see”? The role of spontaneous brain activity in self-generated perception. Brain 144(1):340–353. https://doi.org/10.1093/brain/awaa384CrossRefPubMed

32.

Marschall TM, Ćurčić-Blake B, Brederoo SG, Renken RJ, Linszen MMJ, Koops S, Sommer IEC (2021) Spontaneous brain activity underlying auditory hallucinations in the hearing-impaired. Cortex 136:1–13. https://doi.org/10.1016/j.cortex.2020.12.005CrossRefPubMed

33.

Salbenblatt MJ, Buzan RD, Dubovsky SL (2000) Risperidone treatment for psychosis in end-stage Friedreich’s ataxia. Am J Psychiatry 157(2):303. https://doi.org/10.1176/appi.ajp.157.2.303CrossRefPubMed

34.

Ygland E, Taroni F, Gellera C, Caldarazzo S, Duno M, Soller M, Puschmann A (2014) Atypical Friedreich ataxia in patients with FXN p.R165P point mutation or comorbid hemochromatosis. Parkinsonism Relat Disord 20(8):919–923. https://doi.org/10.1016/j.parkreldis.2014.04.018.

35.

Ganos C, Schöttle D, Zühlke C, Münchau A (2015) Psychosis complicating Friedreich ataxia. Mov Disord Clin Pract 2(1):84–85. https://doi.org/10.1002/mdc3.12115CrossRefPubMed

36.

Chan YC (2005) Aripiprazole treatment for psychosis associated with Friedreich’s ataxia. Gen Hosp Psychiatry 27(5):372. https://doi.org/10.1016/j.genhosppsych.2005.05.004CrossRefPubMed

37.

De Michele G, Filla A, Cavalcanti F, Tammaro A, Monticelli A, Pianese L, Di Salle F, Perreti A, Santoro L, Caruso G et al (2000) Atypical Friedreich ataxia phenotype associated with a novel missense mutation in the X25 gene. Neurology 54(2):496–499. https://doi.org/10.1212/wnl.54.2.496CrossRefPubMed

38.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962. https://doi.org/10.1016/S0140-6736(13)60733-3CrossRefPubMed

39.

Eperjesi F, Akbarali N (2004) Rehabilitation in Charles Bonnet syndrome: a review of treatment options. Clin Exp Optom 87(3):149–152. https://doi.org/10.1111/j.1444-0938.2004.tb03167.xCrossRefPubMed

Titel: Comorbidities in Friedreich ataxia: incidence and manifestations from early to advanced disease stages
verfasst von: Mario Fichera
Anna Castaldo
Alessia Mongelli
Gloria Marchini
Cinzia Gellera
Lorenzo Nanetti
Caterina Mariotti
Publikationsdatum: 02.09.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 12/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06360-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Lymphomatosis cerebri: a rare diffuse leukoencephalopathy you should never miss

Bilateral facial palsy as the first sign of HIV infection

Cutaneous silent period in ATTRv carriers: a possible early marker of nerve damage?

Sensory-motor not length-dependent multineuropathy followed by the syringomyelia-like phenotype: a novel presentation of Tangier disease

Trends of recanalization therapies and state of art for ischemic stroke treatment in Campania region, Italy